Skip to content

Reproductive Outcomes of Different Sperm Selection Techniques for ICSI Patients With Abnormal Sperm DNA Fragmentation.

Reproductive Outcomes of Different Sperm Selection Techniques; Density Gradient Centrifugation, Testicular Sperm, PICSI, and MACS for ICSI Patients With Abnormal Sperm DNA Fragmentation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04482517
Enrollment
320
Registered
2020-07-22
Start date
2017-03-01
Completion date
2018-12-01
Last updated
2020-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Male

Keywords

Sperm DNA fragmentation, PICSI, MACS, Sperm Selection, DGC

Brief summary

Comparing the reproductive outcomes of different sperm selection techniques; Density gradient centrifugation (DGC), Testicular sperm (Testi), Physiological ICSI (PICSI), and Magnetic activated cell sorting (MACS) in abnormal sperm DNA fragmentation (SDF) ICSI patients.

Interventions

Semen processing is done by double layer density gradient method.

Sperm selection by PICSI dishes depending on hyaluronan binding of sperm head

Sperm selection by using Annexin V micro-beads and separation columns

OTHERTesticular sperm

Using testicular sperm retrieved by TESA or TESE

Sponsors

Ganin Fertility Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Female age was ≤37 years * Female should has 5≥ metaphase II oocytes * Males having abnormal SDF levels ≥ 20.3% by TUNEL assay * Abstinence from 1 to 2 days * Males having at least 1 million total motile progressive count

Exclusion criteria

* Leukocytospermia * Presence of varicocele. * Known genetic abnormality * Use of sperm donation or cryopreserved sperm * Use of Oocyte donation * Use of gestational carrier * Presence of any of the endometrial factors that affect embryo implantation such as hydrosalpings, adenomyosis or previous uterine infection * Any contradictions to undergoing in vitro fertilization or gonadotropin stimulation

Design outcomes

Primary

MeasureTime frameDescription
Clinical pregnancy rate14 days following embryo transferDefined as clinical pregnancy per transfer
Implantation rate6- 8 weeks following embryo transferDefined as number of gestational sacs with fetal heart beat, shown by ultrasound in gestational week 6 over number of embryo transferred.
Ongoing pregnancy rate20 weeks of gestationDefined as the proportion of pregnancies that completed more than 20 weeks of gestation

Secondary

MeasureTime frameDescription
Cleavage rate3 daysDefined as the proportion of cleaved embryos on day 3 over the injected oocytes
Miscarriage rate20 weeks of gestationDefined as the proportion of miscarried cases
Blastulation rate5-6 daysDefined as the proportion of blastocysts formed on day 5 or 6 over the cleaved embryos on day 3
High quality blastocyst rate5-6 daysDefined as the assessment of blastocyst quality according to Gardner's criteria into: good, fair or bad in terms of percentage of the total formed blastocysts

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026